Groundbreaking Collaboration to Transform Colorectal Cancer Treatment
First Ascent Biomedical, an innovative biotech company focused on revolutionizing cancer treatment with functional precision medicine, has partnered with a leading cancer nonprofit to initiate an exciting new study. This collaboration aims to significantly enhance the treatment landscape for colorectal cancer patients.
Details of the Study
This prospective feasibility study is fueled by a generous grant of $350,000. Under the leadership of Anjee Davis, the chief executive officer of Fight Colorectal Cancer, the project will harness the advanced xDRIVE tumor profiling technology developed by First Ascent. The goal? To provide rapid and personalized treatment insights for colon cancer patients in Minnesota.
Empowering Patients through Innovation
“Fight CRC is dedicated to enhancing patient empowerment through cutting-edge innovation,” noted Davis. “This financial support highlights our commitment to improving care by focusing on advanced research, especially for those who may have limited treatment options.”
Innovative Technology and Patient-Centric Approach
The enrolled patients, 25 individuals diagnosed with metastatic colorectal cancer, will benefit from an integrated approach combining functional drug testing, genetic analyses, and artificial intelligence. With the insights provided by First Ascent’s xDRIVE platform, oncologists will receive detailed tumor profiling information, enabling them to provide customized treatment strategies. This endeavor aims to improve clinical outcomes significantly.
Expert Team Behind the Study
The clinical aspect of this research is spearheaded by distinguished professionals in the field. Dr. Hao Xie, a specialist in gastrointestinal cancers and precision medicine, leads the clinical operations, with Dr. Boardman contributing his extensive knowledge in cancer genetics and early detection to advance colorectal cancer care. The project will also be overseen by Noah Berlow, the Chief Technology Officer at First Ascent and a principal investigator with vast experience in AI-driven cancer research.
Shaping the Future of Cancer Treatment
In discussion about the collaboration, Jim Foote, the founder and CEO of First Ascent Biomedical, emphasized the significance of their efforts by stating, “Partnering with Fight Colorectal Cancer represents a crucial advancement in how we approach cancer treatment. We are honored to contribute to this vital work.”
Study Enrollment and Patient Participation
Enrollment for this promising study is expected to initiate in the near future. Within nine months, it aims to gather vital data that oncologists will utilize to offer patients advanced treatment recommendations. Interested patients must be evaluated in Rochester, MN, with more information poised to be available on ClinicalTrials.gov shortly.
Frequently Asked Questions
What is the purpose of this collaboration?
The collaboration aims to enhance treatment options for colorectal cancer patients by leveraging advanced technology to deliver personalized treatment insights.
Who is leading the study?
The study is led by Dr. Hao Xie with significant contributions from other experts like Dr. Boardman and Noah Berlow.
How will the study use technology?
It will use First Ascent's xDRIVE platform to provide detailed tumor profiling and treatment information involving AI-driven analyses.
Where will the patients be seen?
Patients interested in participating must be seen in Rochester, MN, where the study will be conducted.
What can participating patients expect?
Participating patients can expect individualized treatment plans based on their unique tumor profiles, enhancing their overall care and outcomes.
